New Migraine Abortive Telcagepant Performs Well In Trials
Last year, we looked at Phase II clinical trials of MK-0974, an investigational oral calcitonin gene-related pepitide (CGRP) receptor antagonist, a new type of Migraine abortive. That medication has now been named telcagepant, and is showing great promise as a new Migraine abortive. When I spoke with lead researcher, Dr. Tony Ho, last year, he... Read more
